Welcome to our dedicated page for SELECTIS HEALTH SEC filings (Ticker: GBCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Selectis Health Inc. filings document a Utah public company that owns and operates healthcare facilities through subsidiaries and reports material events tied to skilled nursing facility assets. Recent 8-K disclosures cover completed dispositions of Georgia skilled nursing facilities, related purchase and sale agreements, subsidiary property interests, proceeds, escrows, debt repayment and other asset-sale terms.
The company’s SEC record also includes governance disclosures for board appointments and resignations, compensatory arrangements for directors, and changes involving executive or board roles. Capital-structure filings describe modifications to senior secured promissory notes, warrant terms and securityholder rights, while Form 12b-25 notices address annual-report timing and financial-statement preparation.
Black Pearl Equities, LLC, through its wholly owned subsidiaries Black Pearl Equities II, LLC and Tortuga Acquisition Sub, Inc., is pursuing a cash tender offer to acquire all issued and outstanding shares of Selectis Health, Inc. common stock. The offer price is $5.75 per Share in cash, without interest and subject to any required tax withholding, on the terms and conditions set out in the Offer to Purchase dated July 13, 2026 and the related Letter of Transmittal.
This amendment updates the existing Schedule TO filing by adding an exhibit: a transcript of a pre-recorded outreach message directed to registered stockholders of Selectis Health. The amendment does not change the stated offer price or core terms of the tender offer; it primarily expands the disclosure record of communications made to stockholders in connection with the offer.
Selectis Health, Inc. is the subject of a cash tender offer by Black Pearl Equities, LLC, Black Pearl Equities II, LLC, and Tortuga Acquisition Sub, Inc. The offer seeks to purchase all issued and outstanding common shares at $5.75 per share in cash, without interest and subject to any required tax withholding, under an Offer to Purchase dated July 13, 2026.
This amendment does not change the economic terms of the offer. It revises wording in the legal and regulatory approvals section by replacing the phrase “OK Required Approvals” with “Required OK Approvals,” leaving all other terms and conditions of the tender offer unchanged.
Selectis Health, Inc. agreed to a cash tender offer by Black Pearl Equities affiliates to acquire up to all outstanding common shares at $5.75 per share. As of June 22, 2026, 3,067,059 shares were outstanding, with 436,491 shares (about 14.2%) locked up under a director support agreement.
The offer, commenced July 13, 2026 and scheduled to expire at 5:00 p.m. New York City time on August 10, 2026, is conditioned on at least 70% of shares being tendered and other closing conditions. After completion, a short-form merger under Utah law would cash out remaining shares at the same price.
The board unanimously determined the merger agreement and transactions are fair and in shareholders’ best interests and recommends that shareholders accept the offer and tender. In reaching this view, it cited ongoing operating losses of $2,729,198 in 2024, $1,564,671 in 2025 and a Q1 2026 operating loss of $1,262,493, as well as an independent Houlihan valuation of the company at $18,403,000, or $5.62 per share, which is below the offer price.
Black Pearl Equities, LLC, through wholly owned subsidiaries Black Pearl Equities II, LLC and Tortuga Acquisition Sub, Inc., has commenced a cash tender offer to acquire all outstanding shares of Selectis Health, Inc. common stock. The offer price is $5.75 per share in cash, without interest and subject to any required tax withholding, on the terms set out in an Offer to Purchase dated July 13, 2026 and a related Letter of Transmittal. The transaction is governed by an Agreement and Plan of Merger dated June 22, 2026 between Black Pearl’s acquisition entities and Selectis Health, and supported by a Tender and Support Agreement with certain Selectis stockholders. A debt commitment letter dated June 17, 2026 provides committed financing for the transaction.
Selectis Health, Inc. entered into a definitive agreement to be acquired by affiliates of Black Pearl Equities through a cash tender offer. Black Pearl will offer $5.75 per share in cash for any and all outstanding Selectis common shares, followed by a merger that will take Selectis private as a wholly owned subsidiary.
The tender offer requires that at least 70% of outstanding shares be validly tendered and not withdrawn, along with other conditions such as minimum unrestricted cash of $6.8 million and required regulatory approvals. The board of directors unanimously approved the deal and recommends that stockholders tender into the offer, which is expected to close in the third quarter of 2026, subject to all conditions.
SELECTIS HEALTH, INC. disclosed the initial holdings of interim CEO and interim CFO Diane Eckhart on a Form 3. The filing shows she directly owns 1,000 shares of the company’s Common Stock, providing a baseline of her equity stake as an executive.
Selectis Health, Inc. reported a sharp swing to profitability for the three months ended March 31, 2026, driven by asset sales rather than core operations. The company generated net income of $6,526,382, or $2.13 basic and $1.90 diluted earnings per share, compared with a net loss of $655,969 a year earlier.
Total revenue fell to $7,288,602 from $10,486,939, a 32% decline, mainly because two Georgia facilities were sold in January 2026. Healthcare revenue dropped to $7,181,161, partly offset by new management fee revenue of $107,441. Operations posted a loss from operations of $1,262,493, but the company recognized a gain on sale of assets of $8,896,309 from the January sale of two Georgia facilities for gross proceeds of $13.2 million.
Asset sales and debt repayment significantly reshaped the balance sheet. Total debt, net of discounts, declined to $22,388,505 from $31,000,562, and total liabilities fell to $29,753,846 from $38,788,531. Stockholders’ equity improved from a deficit of $(6,210,538) at December 31, 2025 to positive equity of $258,344 at March 31, 2026.
Despite these improvements, liquidity remains strained. Cash and cash equivalents were $1,286,452 and restricted cash $192,129, and the company reported negative working capital of about $6.5 million and an accumulated deficit of $14,726,006. Management concluded that substantial doubt exists about Selectis Health’s ability to continue as a going concern and outlined plans to increase occupancy and reimbursement, sell additional facilities, control costs, and seek new capital.
The company continued to reposition its portfolio. As of March 31, 2026 it owned ten long-term care facilities with 712 operating beds and 141 leased beds, primarily in Arkansas, Ohio and Oklahoma, and had completed or agreed to sell all four Georgia skilled nursing facilities for combined gross proceeds of $28.9 million. Management also disclosed a material weakness in disclosure controls and procedures and plans to implement multi-level review and work with third parties to strengthen internal controls.
Selectis Health, Inc. announced that Adam Desmond has resigned from all roles with the company, including CEO, CFO, and director, effective May 14, 2026. A Separation Agreement and Release has been executed between the parties.
On May 15, 2026, the Board appointed Krystal Eckhart, previously a Vice President, as Interim CEO and Interim CFO. Eckhart has more than 15 years of healthcare revenue cycle and financial operations experience and has worked with Selectis Health since 2016, overseeing Medicare and Medicaid operations, audits, financial reporting, and acquisition-related processes.
Selectis Health, Inc. notified the SEC under Rule 12b-25 that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because it has not completed preparation of its unaudited financial statements. The company signed the notice on May 14, 2026.